How Has the Dermatological Drugs Market Size Evolved in Recent Years?
The dermatological drugs market has seen considerable growth due to a variety of factors.
• The market for dermatological drugs has shown substantial growth in the past few years. Expected to expand from a size of $20.06 billion in 2024 to $22.04 billion in 2025, the sector is set to witness a compound annual growth rate (CAGR) of 9.8%.
The prior growth can be traced back to an increased occurrence of skin conditions, advancement in the formulation and delivery of drugs, an upsurge in the consciousness concerning skincare and aesthetics, a rise in the aged demographic, and a growing demand for dermatological products available over-the-counter.
What Are The Predictions for The Dermatological Drugs Market in the Coming Years?
The dermatological drugs market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the dermatological drugs market is projected to experience considerable growth, ballooning to $31.75 billion by 2029 with a compound annual growth rate (CAGR) of 9.6%.
This escalation during the forecasted timeline can be credited to progress in biologics and targeted treatments, increased usage of teledermatology and electronic health, a surge in lifestyle-related skin diseases, escalating demand for individualized and regenerative medicine, and burgeoning research in microbiome-centric dermatological therapies. The forecast period is set to observe specific trends like the delivery of drugs via nanotechnology, dermatological diagnosis powered by artificial intelligence, microbiome-focused treatments, 3D bioprinting for the regeneration of skin, and gene editing & RNA-oriented therapies.
Which Drivers Are Accelerating Growth In The Dermatological Drugs Market?
The increase in popularity for cosmetic dermatology treatments is anticipated to boost the advancement of the dermatological drugs market. Cosmetic dermatology, a specialized field concentrating on improving an individual's aesthetics through various non-surgical processes and treatments, is gaining traction. This surge is largely due to a rise in public awareness about aesthetic enhancements, improvements in skincare technology, and an increasing inclination towards non-invasive methods to improve look and counteract signs of aging. There's a growing demand for cosmetic dermatology treatments, such as anti-aging and skin rejuvenation, which encourages the creation of advanced dermatological drugs that provide safe, effective, and barely invasive solutions. For example, the International Society of Aesthetic Plastic Surgery, a professional organization based in the US, declared in January 2023 that over 12.8 million surgical and 17.5 million non-surgical procedures were carried out worldwide, indicating a 19.3% surge in total procedures relative to the previous report. Furthermore, in 2022, plastic surgeons worldwide are expected to carry out over 14.9 million surgical and 18.8 million non-surgical procedures, translating to an 11.2% increase in total procedures undertaken. Thus, the escalation in cosmetic dermatology procedures is propelling the growth of the dermatological drugs sector.
What Are The Core Segments Of The Global Dermatological Drugs Market?
The dermatological drugs market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Other Drug Classes
2) By Administration: Topical Administration, Oral Administration, Parenteral Administration
3) By Indication: Acne, Psoriasis, Rosacea, Alopecia, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Retinoids: Topical Retinoids, Oral Retinoids
3) By Antibiotics: Topical Antibiotics, Oral Antibiotics
4) By Antifungals: Topical Antifungals, Oral Antifungals
5) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors, Systemic Calcineurin Inhibitors
6) By Other Drug Classes: Biologics, JAK Inhibitors, Antihistamines, Photodynamic Therapy Agents
Pre-Book The Dermatological Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Dermatological Drugs Market Size?
Renowned organizations in the dermatological drugs market are shifting their focus towards the creation of biologic treatments for persistent skin conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. These biologics are designed to target specific immune pathways, providing a more successful and durable solution in comparison to traditional methods of treatment. In September 2024, for example, Eli Lilly and Company, an American pharmaceutical corporation, attained approval for Ebglyss (lebrikizumab), a specialized interleukin-13 (IL-13) inhibitor. This inhibitor is used for the treatment of moderate-to-severe atopic dermatitis in adults and children 12 years and older. This approval signifies a major breakthrough by presenting a fresh biologic treatment alternative for patients who have not obtained sufficient symptom control with topical therapies. Ebglyss is designed to enhance patients' quality of life by alleviating severe itching and skin inflammation resulting from moderate-to-severe atopic dermatitis.
Who Are the Key Players In The Dermatological Drugs Market?
Major companies operating in the dermatological drugs market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• AbbVie Inc.
• Bayer AG
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline Plc
• Eli Lilly and Company
• Amgen Inc.
• Bausch Health Companies Inc.
• Organon International
• Galderma. Incyte Corporation
• Glenmark Pharmaceuticals Ltd.
• Mayne Pharma Group Limited
• Dermavant Sciences Inc.
• Taro Pharmaceutical Industries Ltd.
• Biofrontera AG
• Almirall SA
• UCB SA
• LEO Pharma A/S
• Dermira Inc.
What Are The Regional Insights Into The Dermatological Drugs Market?
North America was the largest region in the dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatological drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
